Physician

Daniel Kasuga, MD

According to 2025 Medicare claims, Daniel Kasuga, MD (NPI: 1568786176) practices ophthalmology in the Las Cruces, NM market, with the plurality of this provider's patient population coming from Dona Ana, NM. This provider's primary affiliated billing organization is SOUTHWEST RETINA CONSULTANTS, P.A. (NPI: 1780797431; TIN: 741997502) and primary practice location at 88001-8268.

Kasuga's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 707 traditional Medicare patients, billed 25,301 HCPCS/CPT codes, and received $2,837,562 in Medicare payments. The top billing code was Q5128 (Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg). Part D data shows 544 prescription claims across 192 beneficiaries totaling $20,655 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 23 records totaling $4,079. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $34,888 to $2,837,562. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $3,498 to $20,655. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.5M$2.9M2015 Medicare payment: $34,888 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $239,543 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,335,774 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,308,937 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $2,788,276 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,697,326 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,425,906 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,623,637 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,913,130 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,837,562 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015265407$34,888
20164732,282$239,543
20176477,019$1,335,774
201877510,061$2,308,937
201975110,903$2,788,276
20206209,440$2,697,326
202160510,504$2,425,906
202268711,655$2,623,637
202368920,173$2,913,130
202470725,301$2,837,562

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$13K$26K2015 Drug cost: $3,498 (USD; Tot_Drug_Cst)2016 Drug cost: $3,961 (USD; Tot_Drug_Cst)2017 Drug cost: $4,803 (USD; Tot_Drug_Cst)2018 Drug cost: $15,927 (USD; Tot_Drug_Cst)2019 Drug cost: $14,189 (USD; Tot_Drug_Cst)2020 Drug cost: $15,460 (USD; Tot_Drug_Cst)2021 Drug cost: $18,035 (USD; Tot_Drug_Cst)2022 Drug cost: $19,092 (USD; Tot_Drug_Cst)2023 Drug cost: $25,552 (USD; Tot_Drug_Cst)2024 Drug cost: $20,655 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015116194$3,498
201657112$3,961
201771144$4,803
2018141392$15,927
2019108277$14,189
2020102275$15,460
2021113313$18,035
2022153420$19,092
2023188538$25,552
2024192544$20,655

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
Q5128Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg2015,415$177
92235Exam of retinal blood vessels using a special camera after injection of a dye225238$116
67028Injection of drug into eye3711,645$110
92014Established patient complete exam of visual system6082,018$98
92250Photography of the retina6782,193$29

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate2046,088$7,027
MoxifloxacinMoxifloxacin Hcl1291,867$3,977
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14410$1,694
Cyclopentolate HclCyclopentolate Hcl491,894$785
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat383,270$525

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.23$4,079Genentech USA, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Daniel Kasuga, MD?

Tedicare shows public-source Medicare data for Daniel Kasuga, MD (NPI 1568786176), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Kasuga, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daniel Kasuga, MD?

Daniel Kasuga, MD is linked to SOUTHWEST RETINA CONSULTANTS, P.A. (billing NPI 1780797431) in the available physician profile data.

Does Daniel Kasuga, MD have Open Payments data?

Daniel Kasuga, MD has 23 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.